143 related articles for article (PubMed ID: 16677592)
1. Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas.
Engelsen IB; Stefansson I; Akslen LA; Salvesen HB
Am J Obstet Gynecol; 2006 Oct; 195(4):979-86. PubMed ID: 16677592
[TBL] [Abstract][Full Text] [Related]
2. Loss of nuclear p16 protein expression is not associated with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis.
Salvesen HB; Das S; Akslen LA
Clin Cancer Res; 2000 Jan; 6(1):153-9. PubMed ID: 10656444
[TBL] [Abstract][Full Text] [Related]
3. GATA3 expression in estrogen receptor alpha-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival.
Engelsen IB; Stefansson IM; Akslen LA; Salvesen HB
Am J Obstet Gynecol; 2008 Nov; 199(5):543.e1-7. PubMed ID: 18599012
[TBL] [Abstract][Full Text] [Related]
4. Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial.
Trovik J; Wik E; Werner HM; Krakstad C; Helland H; Vandenput I; Njolstad TS; Stefansson IM; Marcickiewicz J; Tingulstad S; Staff AC; ; Amant F; Akslen LA; Salvesen HB
Eur J Cancer; 2013 Nov; 49(16):3431-41. PubMed ID: 23932335
[TBL] [Abstract][Full Text] [Related]
5. Expression of the cell cycle regulators p53, p21(WAF1/CIP1) and p16(INK4a) in human endometrial adenocarcinoma.
Buchynska LG; Nesina IP
Exp Oncol; 2006 Jun; 28(2):152-5. PubMed ID: 16837908
[TBL] [Abstract][Full Text] [Related]
6. Molecular and cytokinetic pretreatment risk assessment in endometrial carcinoma.
Silverman MB; Roche PC; Kho RM; Keeney GL; Li H; Podratz KC
Gynecol Oncol; 2000 Apr; 77(1):1-7. PubMed ID: 10739683
[TBL] [Abstract][Full Text] [Related]
7. The expression of p53, p16 proteins and prevalence of apoptosis in oral squamous cell carcinoma. Correlation with mode of invasion grading system.
Tokman B; Gultekin SE; Sezer C; Alpar R
Saudi Med J; 2004 Dec; 25(12):1922-30. PubMed ID: 15711668
[TBL] [Abstract][Full Text] [Related]
8. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
9. The prognostic value of molecular biomarkers in tissue removed by curettage from FIGO stage 1 and 2 endometrioid type endometrial cancer.
Steinbakk A; Skaland I; Gudlaugsson E; Janssen EA; Kjellevold KH; Klos J; Løvslett K; Fiane B; Baak JP
Am J Obstet Gynecol; 2009 Jan; 200(1):78.e1-8. PubMed ID: 18976730
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.
Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA
Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767
[TBL] [Abstract][Full Text] [Related]
11. Angiogenesis, p53, and bcl-2 expression as prognostic indicators in endometrial cancer: comparison with traditional clinicopathologic variables.
Erdem O; Erdem M; Dursun A; Akyol G; Erdem A
Int J Gynecol Pathol; 2003 Jul; 22(3):254-60. PubMed ID: 12819392
[TBL] [Abstract][Full Text] [Related]
12. p16, p14, p53, cyclin D1, and steroid hormone receptor expression and human papillomaviruses analysis in primary squamous cell carcinoma of the endometrium.
Horn LC; Richter CE; Einenkel J; Tannapfel A; Liebert UG; Leo C
Ann Diagn Pathol; 2006 Aug; 10(4):193-6. PubMed ID: 16844559
[TBL] [Abstract][Full Text] [Related]
13. p53 protein overexpression in early stage endometrial cancer.
Kohlberger P; Gitsch G; Loesch A; Tempfer C; Kaider A; Reinthaller A; Kainz C; Breitenecker G
Gynecol Oncol; 1996 Aug; 62(2):213-7. PubMed ID: 8751552
[TBL] [Abstract][Full Text] [Related]
14. Comparison of D&C and hysterectomy pathologic findings in endometrial cancer patients.
Wang X; Huang Z; Di W; Lin Q
Arch Gynecol Obstet; 2005 Jul; 272(2):136-41. PubMed ID: 15666177
[TBL] [Abstract][Full Text] [Related]
15. [A study on expression of tumor suppressor gene p53 in endometrial carcinoma].
Xue F; Jiao S; Zhao F
Zhonghua Fu Chan Ke Za Zhi; 1995 Nov; 30(11):647-50. PubMed ID: 8745486
[TBL] [Abstract][Full Text] [Related]
16. Stathmin overexpression identifies high-risk patients and lymph node metastasis in endometrial cancer.
Trovik J; Wik E; Stefansson IM; Marcickiewicz J; Tingulstad S; Staff AC; Njolstad TS; ; Vandenput I; Amant F; Akslen LA; Salvesen HB
Clin Cancer Res; 2011 May; 17(10):3368-77. PubMed ID: 21242118
[TBL] [Abstract][Full Text] [Related]
17. Prognostic implications of cell cycle-related proteins in primary resectable pathologic N2 nonsmall cell lung cancer.
Mohamed S; Yasufuku K; Hiroshima K; Nakajima T; Yoshida S; Suzuki M; Sekine Y; Shibuya K; Iizasa T; Farouk A; Fujisawa T
Cancer; 2007 Jun; 109(12):2506-14. PubMed ID: 17487846
[TBL] [Abstract][Full Text] [Related]
18. P16 immunoreactivity is an independent predictor of tumor progression in minimally invasive urothelial bladder carcinoma.
Krüger S; Mahnken A; Kausch I; Feller AC
Eur Urol; 2005 Apr; 47(4):463-7. PubMed ID: 15774242
[TBL] [Abstract][Full Text] [Related]
19. [The status of protein P16 and P53 in the surgical margins of laryngeal carcinoma and the association with local recurrence].
Wei B; Tang P; Tu G
Zhonghua Er Bi Yan Hou Ke Za Zhi; 2000 Dec; 35(6):461-3. PubMed ID: 12768762
[TBL] [Abstract][Full Text] [Related]
20. Postmenopausal status, hypertension and obesity as risk factors for malignant transformation in endometrial polyps.
Giordano G; Gnetti L; Merisio C; Melpignano M
Maturitas; 2007 Feb; 56(2):190-7. PubMed ID: 16963204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]